Acyclovirinduced immune thrombocytopenia: Case report and review of the literature
There are a number of medications which can serve as catalysts for druginduced immune thrombocytopenia (DIPT). A minimum of six different mechanisms have been put forward as the means by which druginduced antibodies can encourage platelet destruction, thus emphasising the
complexity of the pathogenesis of DITP. Acyclovir, has been widely used because of its highly potent prohibitive properties for infections caused by HSV and VZV. The common adverse effects of this drug are well known, the severe adverse reactions are mostly related to high dose intravenous
administrations. The immune thrombocytopenia induced by acyclovir is unusual. The authors present a rare clinical case of acyclovirinduced immune thrombocytopenia in a 72yearold female patient with typical herpes zoster treated with acyclovir. The clinical and laboratory findings, taken together
with the transitory relationship between acycolvir and the start of thrombocytopenia, combined with the elimination of the other know sources of thrombocytopenia, allowed us to reach the diagnosis of acyclovirinduced immune thrombocytopenia. An international database search was employed to
complete an extensive review of the current literature. Contemporary information on acyclovirinduced immune thrombocytopenia was collected by the analysis of present day review articles and accessible case reports. The authors found five published cases of acyclovirinduced immune thrombocytopenia.
Analyzing these articles it was concluded that immune thrombocytopenia induced by acyclovir is rare, and an unusual side effect, with good prognosis. Prompt diagnosis is vital to appropriate management, therefore clinicians need to be cognisant of this rare potential adverse reaction.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Dermatology, Dermatology Clinic, ‘George Emil Palade’ University of Medicine, Pharmacy, Science and Technology, 540139 Târgu Mure, Romania
Department of Pharmaceutical Botany and Cell Biology, Faculty of Pharmacy, ‘Carol Davila’ University of Medicine and Pharmacy, 020956 Bucharest, Romania
Department of Dermatology, University of Medicine and Pharmacy, 200349 Craiova, Romania
Medical Department, Faculty of Medicine and Pharmacy, University ‘Dunărea de Jos’, 800010 Galati, Romania
Department of Dermatology, Dermatology Clinic, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania
October 1, 2020
More about this publication?
Experimental and Therapeutic Medicine aims to ensure the expedient publication, in both print and electronic format, of studies relating to biology, gene therapy, infectious disease, microbiology, molecular cardiology and molecular surgery. The journal welcomes studies pertaining to all aspects of molecular medicine, and studies relating to in vitro or in vivo experimental model systems relevant to the mechanisms of disease are also included.
All materials submitted to this journal undergo the appropriate review via referees who are experts in this field. All materials submitted follow international guidelines with regard to approval of experiments on humans and animals.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites